Iliac Stents Market Size & Forecasts 2026-2035, By Segments (Type, Artery Lesions, End-use), Growth Opportunities, Innovation Landscape, Regulatory Shifts, Strategic Regional Insights (U.S., Japan, China, South Korea, UK, Germany, France), and Competitive Dynamics (Medtronic, Boston Scientific, Abbott, Cook Medical, Cordis)

Market Outlook

Iliac Stents Market size is set to grow from USD 981.76 million in 2025 to USD 1.63 billion by 2035, reflecting a CAGR greater than 5.2% through 2026-2035. Industry revenues in 2026 are estimated at USD 1.03 billion.

• Base Year Value (2025): USD 981.76 Million
• CAGR (2026-2035): 5.2%
• Forecast Year Value (2035): USD 1.63 Billion
• Historical Data Period: 2021-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Key Takeaways

• North America region garnered around 43.3% market share in 2025, fueled by high prevalence of vascular diseases and advanced medical facilities.
• Asia Pacific region will observe over 6.5% CAGR through 2035, supported by increasing vascular procedures and improving healthcare access.
• With 49.5% market share in 2025, balloon-expandable stents segment’s growth was led by precision and reliability drive use in iliac artery treatments.
• The common iliac artery lesions segment will hold 58.8% iliac stents market share in 2025, led by high prevalence of iliac artery disease drives treatment demand.
• Securing 63.7% of the market in 2025, hospitals segment was strengthened by advanced facilities and expertise ensure widespread stent use.
• Top companies in the iliac stents market comprise Medtronic (Ireland), Boston Scientific (USA), Abbott (USA), Cook Medical (USA), Cordis (USA), Terumo (Japan), Biotronik (Germany), Atrium Medical (USA), B. Braun (Germany), W. L. Gore (USA).

Market Dynamics

Increasing Incidence of Peripheral Artery Disease

The rising prevalence of peripheral artery disease (PAD) significantly influences the iliac stents market, as it drives demand for effective treatment options. According to the World Health Organization, the global burden of PAD is escalating due to factors such as aging populations, increased prevalence of diabetes, and lifestyle choices. This growing patient base necessitates innovative solutions, propelling investments in research and development from established companies like Medtronic and Boston Scientific. The heightened focus on PAD not only creates opportunities for market players to expand their product lines but also encourages new entrants to develop specialized iliac stents, catering to diverse patient needs. As healthcare systems adapt to manage this increasing burden, the iliac stents market is poised for significant evolution, aligning with broader health initiatives aimed at improving vascular health outcomes.

Advancements in Minimally Invasive Stent Placement Techniques

Innovations in minimally invasive stent placement techniques are reshaping the iliac stents market, enhancing procedural efficiency and patient recovery times. The introduction of advanced imaging technologies and robotic-assisted procedures is making stent placements safer and more precise, as highlighted by the American College of Cardiology. This trend not only improves clinical outcomes but also aligns with patient preferences for less invasive treatments, thereby increasing the overall adoption of iliac stents. Established players are leveraging these advancements to differentiate their offerings, while new entrants can capitalize on the technological gap by introducing novel devices that simplify procedures. As healthcare providers increasingly adopt these techniques, the iliac stents market will likely witness a shift towards more patient-centric solutions, fostering a competitive landscape that emphasizes innovation and quality.

Expanding Access to Vascular Care in Developing Regions

The expansion of vascular care services in developing regions is a pivotal growth driver for the iliac stents market, as it addresses significant healthcare disparities. Organizations like the World Bank are investing in healthcare infrastructure, which facilitates access to essential vascular treatments, including stent placements. This shift not only meets the needs of underserved populations but also creates a burgeoning market for both established players and new entrants who can offer cost-effective and adaptable solutions. By tailoring products to meet local healthcare requirements and regulatory standards, companies can tap into this emerging demand. As access to vascular care continues to improve, the iliac stents market will likely experience increased penetration in these regions, reinforcing the importance of strategic partnerships and localized approaches to healthcare delivery.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Increasing incidence of peripheral artery disease	1.80%	Short term (≤ 2 yrs)	North America, Europe	Medium	Fast
Advancements in minimally invasive stent placement techniques	1.50%	Medium term (2–5 yrs)	Asia Pacific, North America	Low	Moderate
Expanding access to vascular care in developing regions	1.00%	Long term (5+ yrs)	Latin America, MEA	Medium	Slow

Industry Restraints:

Regulatory Compliance Challenges

The iliac stents market is significantly constrained by stringent regulatory compliance requirements imposed by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulations necessitate extensive clinical trials, rigorous safety assessments, and comprehensive documentation, which can prolong the time to market for new products. For instance, the FDA’s Pre-Market Approval (PMA) process is notably more demanding than the 510(k) pathway, leading to hesitance among manufacturers to innovate. This regulatory burden not only increases operational costs but also discourages new entrants who may lack the resources to navigate complex compliance landscapes. As a result, established companies often dominate the market, stifling competition and slowing the introduction of potentially groundbreaking technologies. In the near to medium term, these compliance challenges are likely to persist, as regulatory bodies continue to prioritize patient safety over market speed, thereby shaping the strategic landscape of the iliac stents market.

Supply Chain Disruptions

The iliac stents market faces significant challenges due to ongoing supply chain disruptions, exacerbated by global events such as the COVID-19 pandemic and geopolitical tensions. These disruptions have led to increased lead times and costs for raw materials, which are critical for stent production. For example, manufacturers like Medtronic have reported difficulties in sourcing essential components, resulting in production delays and inventory shortages. Such supply chain vulnerabilities not only affect established players but also pose substantial barriers for new entrants attempting to penetrate the market with innovative offerings. As companies scramble to secure reliable suppliers, the focus on cost efficiency and sustainability may lead to further operational inefficiencies. Looking ahead, the emphasis on building resilient supply chains will be crucial, as market participants seek to mitigate risks and ensure consistent product availability, ultimately influencing competitive dynamics and market growth.

Regional Forecast

North America Market Statistics:

North America represented more than 43.3% of the global iliac stents market in 2025, establishing itself as the largest region. This dominance can be attributed to the high prevalence of vascular diseases and the presence of advanced medical facilities that foster innovative treatment options. The region's healthcare infrastructure supports rapid adoption of cutting-edge technologies, driven by evolving consumer preferences towards minimally invasive procedures. Additionally, regulatory frameworks in the U.S. and Canada have evolved to facilitate quicker approvals for new medical devices, enhancing market dynamics. With increasing investments in healthcare and a push towards sustainable practices, North America is poised to offer significant opportunities in the iliac stents market as stakeholders seek to address the growing demand for effective vascular solutions.

The United States anchors the North American iliac stents market, propelled by its robust healthcare system and a strong emphasis on research and development. The high prevalence of vascular diseases, coupled with a well-established network of hospitals and specialized clinics, creates a conducive environment for the growth of the iliac stents market. Companies like Medtronic and Boston Scientific are leveraging this landscape by introducing innovative stent technologies that cater to specific patient needs, as noted in reports from the American Heart Association. Furthermore, the U.S. regulatory environment encourages rapid innovation, allowing companies to bring advanced solutions to market swiftly. This strategic positioning reinforces the U.S.'s pivotal role in the regional market, highlighting opportunities for growth that align with the broader trends in healthcare advancements and patient-centered care.

Asia Pacific Market Analysis:

Asia Pacific emerged as the fastest-growing region in the iliac stents market, posting a robust CAGR of 6.5%. This growth is primarily driven by the increasing number of vascular procedures and improving healthcare access across the region. The rising prevalence of vascular diseases, combined with advancements in medical technology, has led to a heightened demand for effective treatment options, including iliac stents. Furthermore, the region's diverse population and varying healthcare policies are fostering a competitive environment that encourages innovation and accessibility. Notably, organizations such as the World Health Organization have emphasized the need for improved healthcare infrastructure, which aligns with the growing investments in medical facilities and technologies, ultimately enhancing patient outcomes and satisfaction. As the Asia Pacific region continues to prioritize healthcare advancements and accessibility, it presents significant opportunities for growth in the iliac stents market.

Japan plays a pivotal role in the Asia Pacific iliac stents market, characterized by its advanced healthcare system and high demand for innovative medical solutions. The country's increasing vascular procedures are driven by an aging population and a growing awareness of vascular health, leading to a shift in consumer preferences towards minimally invasive treatment options. Regulatory bodies, such as the Pharmaceuticals and Medical Devices Agency, are actively facilitating the approval of new medical technologies, which enhances market dynamics. For instance, recent initiatives aimed at streamlining the approval process for medical devices have resulted in quicker access to innovative iliac stents, as reported by the Japan Medical Device Industry Association. This environment not only supports local manufacturers but also attracts foreign investment, further bolstering Japan's position in the regional market.

China is another key player in the Asia Pacific iliac stents market, driven by its significant healthcare reforms and a rising demand for advanced medical technologies. The government's commitment to improving healthcare access has led to increased funding for medical infrastructure, which is crucial for supporting the growing number of vascular procedures. Consumer behavior is shifting towards seeking high-quality healthcare solutions, with an emphasis on innovative products that provide better clinical outcomes. The National Health Commission of China has reported a rise in the adoption of minimally invasive procedures, reflecting a broader trend towards patient-centric care. This favorable regulatory environment, combined with a strong push for technological advancements, positions China as a vital contributor to the growth of the iliac stents market in the region. The strategic implications of these developments underscore the importance of both Japan and China in capitalizing on the expanding opportunities within the Asia Pacific iliac stents market.

Europe Market Trends:

The iliac stents market in Europe held a commanding share, driven by a robust healthcare infrastructure and increasing prevalence of vascular diseases. This region is particularly significant due to its advanced technological landscape and stringent regulatory standards that ensure high-quality medical devices. Recent shifts in consumer preferences towards minimally invasive procedures have spurred demand, while sustainability priorities are influencing manufacturers to adopt eco-friendly materials in stent production. The European Society of Cardiology has noted a rise in cardiovascular conditions, further amplifying the need for innovative solutions. With a strong emphasis on research and development, Europe is poised for continued growth, presenting substantial opportunities for investors and stakeholders in the iliac stents market.

Germany plays a pivotal role in the iliac stents market, characterized by its significant investment in healthcare technology and innovation. The country’s stringent regulatory framework, enforced by the Federal Institute for Drugs and Medical Devices (BfArM), ensures that only the highest quality stents are approved for use, fostering consumer trust and market stability. Additionally, Germany's aging population is driving demand for vascular interventions, creating a favorable environment for new product launches. Companies like Medtronic and Boston Scientific are enhancing their competitive edge through advanced research initiatives, positioning Germany as a key player in the European market. This dynamic landscape not only bolsters the country’s market share but also aligns with broader regional opportunities for growth in the iliac stents market.

France also holds a significant position in the iliac stents market, supported by a well-established healthcare system and a growing emphasis on preventive care. The French National Authority for Health (HAS) has been proactive in promoting innovative medical technologies, facilitating quicker access to advanced stenting solutions. Cultural shifts towards proactive health management are evident, with increasing patient awareness driving demand for effective vascular treatments. Notable advancements from local firms such as Biotronik are enhancing competition and fostering innovation. The interplay of these factors underscores France's strategic importance in the regional market, reinforcing the potential for collaborative growth opportunities across Europe in the iliac stents sector.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Nascent	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Supportive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Weak	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Stable	Strong	Weak	Weak

Segmentation Analysis

 

Analysis by Type

The iliac stents market is predominantly led by balloon-expandable stents, which captured a commanding 49.5% share in 2025. This segment's leadership can be attributed to the precision and reliability that balloon-expandable stents offer in iliac artery treatments, making them the preferred choice among healthcare providers. The growing emphasis on patient outcomes and safety has influenced customer preferences, driving demand for these stents. Additionally, advancements in manufacturing processes and materials have enhanced the performance of these devices, aligning with sustainability priorities in the healthcare sector. Companies like Boston Scientific have reported increased adoption of their balloon-expandable stents, reflecting their competitive edge in innovation. This segment presents significant opportunities for established firms to reinforce their market positions while emerging players can capitalize on advancements to introduce novel solutions. Given the ongoing improvements in technology and rising treatment standards, balloon-expandable stents are expected to remain a critical component of the iliac stents market in the near to medium term.

Analysis by Artery Lesions

The iliac stents market is significantly influenced by common iliac artery lesions, which represented more than 58.8% of the market share in 2025. This segment leads due to the high prevalence of iliac artery disease, which drives a consistent demand for effective treatment options. As healthcare systems increasingly focus on addressing vascular diseases, there is a growing recognition of the need for reliable stenting solutions. The demographic shift towards an aging population further exacerbates the demand, as older individuals are more susceptible to arterial diseases. Regulatory bodies such as the FDA have emphasized the importance of timely interventions, thereby encouraging innovation in treatment methodologies. This segment not only offers strategic advantages for established manufacturers but also opens avenues for startups to introduce targeted therapies. With the continuous rise in awareness and treatment initiatives, common iliac artery lesions are poised to sustain their relevance in the iliac stents market.

Analysis by End-use

The iliac stents market is chiefly dominated by hospitals, which accounted for an impressive 63.7% share in 2025. This segment's dominance is largely attributed to the advanced facilities and specialized expertise available in hospital settings, ensuring the widespread use of stents in various procedures. The increasing complexity of vascular interventions necessitates a robust infrastructure and skilled personnel, which hospitals are uniquely positioned to provide. Furthermore, the trend towards integrated healthcare delivery models enhances the collaboration between hospitals and device manufacturers, facilitating better patient care. Industry leaders like Medtronic have noted that hospitals are increasingly adopting innovative stenting technologies, reflecting a shift towards evidence-based practices. The strategic advantages for both established firms and new entrants lie in the potential for partnerships and collaborations that enhance service delivery. As healthcare continues to evolve with a focus on quality and efficiency, the hospital segment is expected to maintain its pivotal role in the iliac stents market.

Report Segmentation
Segment	Sub-Segment
Type	Self-expandable stents, Balloon-expandable stents, Covered stents
Artery Lesions	Common iliac artery lesions, Severe calcified lesions, Complete obstructive lesions
End-use	Hospitals, Ambulatory surgical centers, Other end-users

Competitive Landscape

Key players in the iliac stents market include Medtronic, Boston Scientific, Abbott, Cook Medical, Cordis, Terumo, Biotronik, Atrium Medical, B. Braun, and W. L. Gore. These companies are recognized for their innovative approaches and robust product portfolios, which significantly shape the competitive landscape. Medtronic and Boston Scientific stand out due to their extensive research and development capabilities, enabling them to introduce advanced stenting solutions that address complex vascular conditions. Abbott and Cook Medical also hold substantial market influence, focusing on enhancing patient outcomes through innovative technologies and comprehensive clinical support. The presence of established players like Cordis and Terumo further underscores the market's competitive nature, with each company leveraging its strengths to maintain a prominent position in the industry.

The competitive environment in the iliac stents market is characterized by dynamic strategic initiatives that enhance innovation and market presence. Companies are increasingly engaging in collaborative efforts that foster technological advancements, while also exploring mergers and acquisitions to consolidate their market share. Notably, recent product launches from key players reflect a commitment to addressing unmet clinical needs through cutting-edge designs and materials. This focus on innovation not only strengthens their competitive positioning but also drives the overall evolution of stenting technologies, ensuring that they remain at the forefront of the industry. Furthermore, investments in research and development are paving the way for breakthroughs that could redefine treatment protocols and improve patient care.

Strategic / Actionable Recommendations for Regional Players

In North America, fostering partnerships with healthcare institutions can enhance clinical trial opportunities, allowing for the rapid adoption of innovative stenting technologies. Emphasizing the development of minimally invasive solutions could cater to the growing demand for less traumatic procedures. In the Asia Pacific region, tapping into emerging markets presents a unique opportunity for growth; focusing on localized product adaptations and educational initiatives can address specific patient needs while building brand loyalty. Lastly, in Europe, leveraging advancements in digital health technologies could facilitate better patient monitoring and outcomes, positioning companies as leaders in integrated care solutions. By responding proactively to competitive dynamics, companies can enhance their market resilience and drive sustained growth.